- PHAXIAM Therapeutics annonce le recrutement du premier patient dans l’étude de phase 1 dans l’endocardite infectieuse causée par le Staphylococcus aureus
- PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
- Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 mars 2024
- PHAXIAM Therapeutics annonce le dépôt de son Document d’Enregistrement Universel (URD) 2023
- PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
- PHAXIAM Announces 2023 Full-Year Results and Provides Business Update
- PHAXIAM Therapeutics publie ses résultats annuels 2023 et fait le point sur ses activités
- PHAXIAM Therapeutics annonce la réalisation du retrait volontaire de ses « American Depository Shares » du Nasdaq Stock Market
- PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
More ▼
Key statistics
On Tuesday, Phaxiam Therapeutics SA (PHXM:PAR) closed at 2.96, 13.85% above the 52 week low of 2.60 set on Sep 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.90 |
---|---|
High | 2.94 |
Low | 2.90 |
Bid | 2.89 |
Offer | 2.97 |
Previous close | 2.96 |
Average volume | 3.09k |
---|---|
Shares outstanding | 6.08m |
Free float | 5.60m |
P/E (TTM) | -- |
Market cap | 17.98m EUR |
EPS (TTM) | -5.56 EUR |
Data delayed at least 15 minutes, as of Apr 30 2024 16:35 BST.
More ▼